ArticleJournal of experimental & clinical cancer research : CR2022

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.

Antonio C Fuentes-Fayos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.